<Room "Amagi">  
**Special Session 1**

8:35-9:05  **Chair:** Kinuko Mitani (Dokkyo Medical University School of Medicine)

**SS-1**  
Precision medicine in pediatric acute lymphoblastic leukemia: a strategy to cure all patients and decrease adverse effects  
Hiroto Inaba (St. Jude Children’s Research Hospital, USA)

<Room "Amagi">  
**Asia-Pacific Session 1 : Bone Marrow Failure**

9:15-10:35  **Chairs:** Yoshiyuki Takahashi (Nagoya University Graduate School of Medicine)  
Shouichi Ohga (Kyushu University Graduate School of Medical Sciences)

9:15-9:35  **APS I-1**  
Randomized trial of two dosages of rabbit antithymocyte globulin in patients with aplastic anemia  
Atsushi Narita (Nagoya University Graduate School of Medicine)

9:35-9:55  **APS I-2**  
Upfront alternate donor HSCT for patients with severe aplastic anemia: multi-center prospective clinical trial outcome  
Jing Chen (Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, China)

9:55-10:15  **APS I-3**  
Factors affecting response to eltrombopag in patients with refractory aplastic anemia  
Ken Ishiyama (Kanazawa University Hospital)

10:15-10:35  **APS I-4**  
Safety and efficacy of romiplostim in aplastic anemia refractory to immunosuppressive therapy  
Jong Wook Lee (Seoul St. Mary’s Hospital, The Catholic University of Korea, Korea)

<Room "Shiosai">  
**Asia-Pacific Session 2 : Neoplastic Lymphoid Cells**

9:15-10:35  **Chairs:** Shigeru Chiba (Faculty of Medicine, University of Tsukuba)  
Motoko Yamaguchi (Mie University Graduate School of Medicine)

9:15-9:35  **APS II-1**  
Establishment of a mouse model of B-cell lymphoma using an in vitro retroviral transduction system  
Kotaro Arita (Toyama University Graduate School of Medicine and Pharmaceutical Sciences)

9:35-9:55  **APS II-2**  
Exploiting weaknesses in the malignant lymphoid cell for targeted therapy  
Constantine S Tam (St. Vincent Hospital, Peter MacCallum Cancer Center and University of Melbourne, Australia)

9:55-10:15  **APS II-3**  
Genome-based medicine in peripheral T-cell lymphomas  
Mamiko Sakata-Yanagimoto (Faculty of Medicine, University of Tsukuba)

10:15-10:35  **APS II-4**  
Immune-Checkpoint Inhibition in T-cell and NK-cell Malignancies  
Yok-Lam Kwong (Queen Mary Hospital, China)

10:35-10:45  **Break** (10min)
Plenary Session 1: T Cells (Normal, Pathologic, and Modified) and Antigen-Presenting Cells

10:45-12:25 Chairs: Norimitsu Kadowaki (Faculty of Medicine, Kagawa University) Itaru Matsumura (Kindai University Faculty of Medicine)

10:45-11:10 PS-I-1 In vivo modulation of regulatory and effector T cell homeostasis for maximization of GVL effect in allogeneic HSCT Ken-ichi Matsuoka (Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)

11:10-11:35 PS-I-2 Dendritic cell vaccination: correlation of clinical effects with T-cell response Zwi N. Berneman (Antwerp University Hospital and University of Antwerp, Belgium)

11:35-12:00 PS-I-3 The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T-cell therapy Naoki Hosen (Osaka University Graduate School of Medicine)

12:00-12:25 PS-I-4 Targeting tissue residence and innate immunity towards protective immunity Madhav Dhodapkar (Emory University, USA)

12:25-12:35 Break- Distribute box lunch (10min)

Luncheon Seminar 1

Co-Sponsored by Eisai Co., Ltd.

12:35-13:20 Chair: Kinuko Mitani (Dokkyo Medical University School of Medicine)

Precision medicine of lymphoma based on genetics Ulrich Jäger (Medical University of Vienna, Austria)

Luncheon Seminar 2

Co-Sponsored by Chugai Pharmaceutical Co., Ltd.

12:35-13:20 Chair: Norio Komatsu (Juntendo University School of Medicine)

Future prospects for targeting apoptosis in hematopoietic malignancies Anthony G. Letai (Dana-Farber Cancer Institute, Harvard Medical School, USA)

Poster Viewing

13:20-14:10 Hematopoiesis/Regenerative cell therapies

P1-1 Novel lymphoid pathway of human dendritic cells Keiki Nagaharu (Department of Hematology and Oncology, Mie University Graduate School of Medicine, Japan)

P1-2 Three cases of aplastic anemia with abnormal karyotype treated with eltrombopag Yusuke Uchibori (Department of Hematology, NTT Medical Center Tokyo, Japan)

P1-3 Adult human hematopoietic stem cells can produce B1 cells Yuki Kageyama (Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan)

P1-4 Notch signaling in nestin-expressing bone marrow stromal cells supports erythropoietic niche Tatsuhito Sakamoto (Department of Hematology, Faculty of Medicine, University of Tsukuba / Department of Transfusion Medicine, University of Tsukuba Hospital, Japan)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-5</td>
<td>Regeneration of invariant NKT cells with three-dimensional culture system</td>
<td>Sara Shiina (Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan)</td>
<td></td>
</tr>
<tr>
<td>Acute leukemia/MDs/MPN (basic and clinical)</td>
<td><strong>P2-1</strong> Prognostic impact of time from diagnosis to initial treatment for acute myeloid leukemia</td>
<td>Yoshimasa Kamoda (Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-2</strong> Expression of CD25 fluctuates in the leukemia-initiating cell population of CD25-positive AML</td>
<td>Yuki Kageyama (Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-3</strong> MPL overexpression is a mechanism of ruxolitinib-resistance in CALR mutant cells</td>
<td>Shunichiro Yasuda (Department of Immunotherapy for hematopoietic disorders/hematology/ comprehenshensive pathology, Tokyo Medical and Dental University (TMDU), Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-4</strong> S100A16 suppresses the growth and survival of leukaemia cells and correlates with relapse and relapse free survival in adults with philadelphia chromosome negative B-cell acute lymphoblastic leukaemia</td>
<td>Jing Zhang (Peking University Peoples Hospital, Peking University Institute of Hematology / Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation / Collaborative Innovation Center of Hematology, Peking University, Beijing, China)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-5</strong> First-line nilotinib therapy and FRET-based drug sensitivity test for patients with newly-diagnosed CML</td>
<td>Takeshi Kondo (Department of Hematology and Blood Disorders Center, Aikiku Hospital, Japan / Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-6</strong> Homeobox transcription factor HHEX promotes myeloid leukemia in cooperation with mutant ASXL1</td>
<td>Reina Takeda (Division of Cellular Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-7</strong> The link between IL-1β and acute myocardial infarction in CML patients treated with TKI</td>
<td>Hirotaka Mori (Department of Hematology, Fukushima Medical University / Department of Hematology, Shirakawa Kosei General Hospital, Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-8</strong> Prognostic significance of a host-related factor in MDS patients treated with azacitidine</td>
<td>Yasuyuki Takahashi (Department of Hematology, Saitama Medical Center, Saitama Medical University, Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-9</strong> Mutations in epigenetic and splicing related genes among japanese overt and prefibrotic primary myelofibrosis using target sequencing</td>
<td>Soji Morishita (Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-10</strong> Reduced-intensity treatment of RUNX1-RUNX1T1 acute myeloid leukemia in adult down syndrome</td>
<td>Ichita Hasegawa (Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-11</strong> Optimal interval for detection of molecular relapse after stop of TKI in Ph+ leukemia calculating by MRD kinetics</td>
<td>Koichi Miyamura (Department of Hematology, Japanese Red Cross Nagoya First Hospital, Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-12</strong> Myeloproliferative hematopoiesis in calreticulin mutant mice</td>
<td>Kazuhiko Ikeda (Fukushima Medical University, Dept. Blood Transfusion and Transplantation Immunology, Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>P2-13</strong> Haploinsufficiency of CALR confers HSCs with a clonal advantage over wild-type cells and compensates for the functions of HSCs impaired by the CALR mutation</td>
<td>Kotaro Shide (Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Japan)</td>
<td></td>
</tr>
</tbody>
</table>
The presence of minimal residual disease, as determined by highly sensitive quantitation of NPM1-mutation, provided powerful prognostic information in acute myeloid leukemia
Atsushi Marumo (Department of Hematology, Nippon Medical School, Tokyo, Japan)

18F-FLT PET for pancytopenia-initial experience
Toshiki Tasaki (Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Japan)

Concurrent loss of Tet2 and Tet3 promotes leukemogenesis in mice
Raksha Shrestha (Graduate School of Comprehensive Human Sciences, Department of Hematology, University of Tsukuba, Tsukuba, Japan)

Pharmacological activation of p53 enhances NK cell activity and inhibits the development of AML
Yasutaka Hayashi (Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan)

Clinical significance of myelofibrosis in newly diagnosed multiple myeloma in the era of novel drugs
Megumi Koshiishi (Department of Hematology & Oncology, University of Yamanashi, Japan)

Tamoxifen enhances romidepsin-induced apoptosis in T-cell leukemia and lymphoma cells
Chinadol Wanitpongpun (1Departments of Oncology/Hematology, Faculty of Medicine, Shimane University, Izumo, Shimane, Japan, 2Hematology unit / Department of Internal Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand)

Infiltration of effector regulatory T cells is associated with poor prognosis in diffuse large B-cell lymphoma, not otherwise specified
Shoko Nakayama (Division of Hematology and Rheumatology, Kindai University Faculty of Medicine, Japan)

TFL deletion induces incredible CXCL13 secretion and cachexia in VavP-Bcl2 transgenic mice
Yoshio Katayama (Kobe University Graduate School of Medicine, Hematology, Department of Medicine, Japan)

Exosomes derived from cancer associated fibroblasts elicit drug resistance of B-cell lymphoma cells through modulation of drug transporter
Shunsuke Kunou (Department of Hematology and Oncology, Nagoya University Graduate School of Medical Sciences, Japan)

The analyses of expression levels, mutations, and methylation status of CRBN-related genes pre- and post-lenalidomide treatment in multiple myeloma
Takuto Tachita (Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Japan)

Bi-allelic loss of FAM46C promotes the proliferation of multiple myeloma cells with concomitant upregulation of PI3K-AKT signaling
Akinobu Ota (Department of Biochemistry, Aichi Medical University, Japan)

Low IP-10/CXCL10 levels are associated with good responses to lenalidomide plus low-dose dexamethasone for relapsed and/or refractory multiple myeloma
Nami Sakamoto (Division of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan)

Clinical factors to predict outcome after mogamulizumab monotherapy in adult T-cell leukemia-lymphoma
Jun Nakashima (Department of Hematology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan)

Comparison of different definition of GELF criteria in patients with follicular lymphoma treated with first-line immune chemotherapy
Toko Saito (Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan)

Prognostic factors for smoldering-type adult T-cell leukemia-lymphoma
Ayumu Kubota (Department of Hematology, Imamura General Hospital, Kagoshima, Japan)
P3-12 Characteristics of nodular lymphocyte predominant Hodgkin lymphoma: A single center experience
Harumi Kato (Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan)

P3-13 Seven-year follow-up of 101 patients with advanced NK/T-cell lymphoma: NKEA study
Kana Miyazaki (Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan)

P3-14 Targeted sequencing and IgH rearrangement status revealed branching evolution pattern of SMZL and DLBCL
Manabu Kusakabe (Department of Hematology, Faculty of medicine, University of Tsukuba, Tsukuba, Japan)

Non-malignant hematological disorders
P4-1 The first case of e-cigarette-induced polycythemia
Marika Okuni-Watanabe (Department of Hematology, Kobe City Medical Center West Hospital, Japan)

P4-2 CD3+ B-1a cells as an indicator of disease progression in autoimmune-prone mice
Hidemi Toyoda (Department of Pediatrics, Mie University Graduate School of Medicine, Japan)

P4-3 Combined iron chelation therapy in women with transfusion dependent thalassaemia during pregnancy: a single centre observational study
Gilbert Wilfred (Haematology Unit, Department of Medicine, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia)

P4-4 The utility of revised diagnostic criteria for DIC in development of coagulopathy with haematological malignancies
Kayo Harada-Shirado (Department of Hematology, Fukushima Medical University, Japan)

P4-5 Treatment of adult hemophagocytic lymphohistiocytosis adapting HLH-94 protocol with dose reduction or omission of etoposide
Gilbert Wilfred (Haematology Unit, Department of Medicine Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia)

P4-6 A study of impact of haemophilia on state-trait anxiety in young adults in north india and some underlying factors
Naresh Gupta (Maulana Azad Medical College, Haemophilia Centre, Lok Nayak Hospital, New Delhi, India)

P4-7 A comparison of the accuracy in detecting minor PNH clones in patients with bone marrow failure between two high-sensitivity flow cytometry assays: CLSI and OPTIMA
Kohei Hosokawa (Kanazawa University, Kanazawa, Japan / Japan PNH Study Group, Tokyo, Japan)

Hematopoietic stem cell transplantation
P5-1 Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B-cell lymphoma
Jin Seok Kim (Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea)

P5-2 A novel unifrac-based analytical method for determining sequential changes in gut microbiota after hematopoietic stem cell transplantation
Shinsuke Kusakabe (Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan)

P5-3 M2 macrophage attenuates severity of acute GVHD in murine model of allogeneic HSCT
Ryo Hanaki (Department of Pediatrics, Mie University Graduate School of Medicine, Mie, Japan)

P5-4 Post-transplant cyclophosphamide treatment for murine MHC-haploidentical bone marrow transplant model using a recipient-derived tumor cell line
Komei Nishimura (Department of Hematology and oncology, Mie University Graduate School of Medicine, Japan)

P5-5 Stability of tacrolimus concentration early after allogeneic hematopoietic stem cell transplantation reduces the risk of acute GVHD
Motohito Okabe (Japanese Red Cross Nagoya First Hospital, Department of Hematology, Nagoya, Japan)

-Hematopoietic stem cell transplantation
Ruxulotinib is effective in severe chronic graft versus host disease of skin
Gilbert Wilfred (Haematology Unit, Department of Medicine Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia)

Murine steroid refractory GVHD model
Tomomi Toubai (Department of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan)

Low-dose interleukin-2 therapy activates circulating T follicular regulatory cells (cTFR) and suppresses circulating T follicular helper cells (cTFH) in patinet with chronic GvHD
Yusuke Kamihara (Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA / Harvard Medical School, Boston, MA, USA / Department of Hematology, National Cancer Hospital East, Kashiwa, Chiba, Japan)

Association between heparanase gene polymorphism and the development of acute and chronic GVHD
Masahiro Ogawara (Department of Hematology, Sapporo Hokuyu Hospital, Japan)

Immunotherapies/gene therapies

Clinical results and immunological features of WT1 short peptide vaccination against acute myeloid leukemia patients after chemotherapy
Jun Nakata (Department of Biomedical Informatics, Osaka University, Japan)

A determining factor of susceptibility to oncolytic HSV-1 in hematologic malignancies
Ryo Ishino (Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan / Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan)

Characteristics of cytotoxic T cells against myeloma cells for adoptive immunotherapy
Saku Saito (Division of Clinical Physiology and Therapeutics, Keio University, Faculty of Pharmacy, Tokyo, Japan)

A multi-antigen recognition CAR-T cell system using protease mediated protein cleavage
Satoru Aoyama (Department of Immunotherapy for hematopoietic disorders, Tokyo Medical and Dental University (TMDU), Japan)

Daratumumab, a novel CD38-targeting monoclonal antibody, demonstrates potent antitumor activity against primary effusion lymphoma
Jutatip Panaampon (Division of Hematopoiesis, Joint Research Center for Chronic Viral Infection, Kumamoto University, Japan)

Novel treatment strategy using HTLV-1 p40tax-specific TCR gene-modified allogeneic γ/δ -T cells for the treatment of adult T-cell leukemia/lymphoma
Hiroshi Fujiwara (Department of Personalized Cancer Immunotherapy / Department of Immunogene therapy, Mie University, Japan)

Durvalumab disarms T-cell suppression via PD-L1 upregulation by immunomodulatory drugs on myeloma cells
Mariko Ishibashi (Department of Hematology, Nippon Medical School, Tokyo, Japan / Department of Microbiology and Immunology, Nippon Medical School, Tokyo, Japan)

Development of adoptive cell therapy with allogeneic TCR gene-modified “stealth T cells” deficient in endogenous TCR and HLA class I molecules
Hiroaki Ikeda (Department of Oncology, Nagasaki University Graduate School of Biomedical Sciences, Japan)

Utilization of a novel sendai virus vector for hemophilia a in vivo gene therapy
Yuni Yamaki (Department of Pediatrics, University of Tsukuba Hospital, Japan)

A novel intracellular tumor antigen-targeted CAR-T therapy utilizing GITR signaling domain for enhanced therapeutic activity towards human solid tumors
Yoshihiro Miyahara (Department of Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Mie, Japan)
Infiltrating CCR2+ monocytes and fibrocytes contribute to colon fibrosis by inhibiting degradation of collagen through the production of tissue inhibitor of matrix metalloproteinase-1
Kensuke Hachiya (Department of Hematology and Oncology, Mie University Graduate School of Medicine, Japan)

Long-term eradication of extranodal NK/T cell lymphoma, nasal type, by iPSC-derived Epstein-Barr virus - specific rejuvenated T cells in vivo
Miki Ando (Department of Hematology, Juntendo University School of Medicine, Japan / Division of Stem Cell Therapy, The Institute of Medical Science, The University of Tokyo, Japan)

Monitoring of persistent CTLs over 10 years using MLPC after WT1 peptide vaccine in a CML patient
Tatsuya Suwabe (Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan)

The composite CD79A/CD40 costimulatory endodomain enhances CD19 chimeric antigen receptor T-cell proliferation and survival
Jakrawadee Julamanee (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Japan)

High-throughput drug screening by pluripotent stem cell derived disease models identify disease specific drug candidate of Nakajo-Nishimura syndrome
Naoya Kase (Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan)

Developing therapeutic strategies for genetically-complex acute myeloid leukemia
Fumihiko Ishikawa (RIKEN Center for Integrative Medical Sciences)

Stem cells in human AML
Ravi Majeti (Stanford University School of Medicine, USA)

Germline DDX41 mutations in the Japanese populations
Seishi Ogawa (Graduate School of Medicine, Kyoto University / Karolinska Institute, Sweden)

Guiding blood cancer therapy with mitochondrial BH3 profiling
Anthony G. Letai (Dana-Farber Cancer Institute, Harvard Medical School, USA)

Establishment of a new therapeutic cancer vaccine inducing multifunctional immunity, "artificial adjuvant vector cells (aAVG)"
Shin-ichiro Fuji (RIKEN Center for Integrative Medical Sciences (IMS) / RIKEN Drug Discovery and Medical Technology Platforms (DMP))

Novel ways to activate NK cells with specificity to treat cancer
Jeffrey S. Miller (University of Minnesota, Masonic Cancer Center, USA)
16:55-17:20
PS-II-3  Turning stem cells into platelets for next generation transfusion
Koji Eto (Department of Clinical Application, CiRA, Kyoto University, Graduate School of Medicine / Graduate School of Medicine, Chiba University)

17:20-17:45
PS-II-4  Notch signaling: enhancing the ex vivo generation of cells for therapeutic application
Irwin D. Bernstein (Fred Hutchinson Cancer Research Center, University of Washington, USA)

17:45-17:55
Break (10min)

<Room “Amagi”>  Oral Session from Poster Presentation:
Hematological Malignancies and Their Therapies, Clonal Hematopoiesis

17:55-18:05  Chairs: Masahiro Hirayama (Mie University Graduate School of Medicine)
Tetsuya Nosaka (Mie University Graduate School of Medicine)

OS-1  Detection of subclonal SETBP1 and JAK3 mutations in patients with juvenile myelomonocytic leukemia using droplet digital PCR
Manabu Wakamatsu (Department of Pediatrics, Nagoya University Graduate School of Medicine)

18:05-18:15  Special AT-rich sequence binding protein 1 is involved in the formation of germinal center B cells in the murine spleen
Takayuki Ozawa (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)

18:15-18:25  STAP-1 is required for maintenance of leukemic stem cells in chronic myeloid leukemia
Jun Toda (Department of Hematology and Oncology, Osaka University Graduate School of Medicine)